Pexidartinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 204 publications
Corrigendum to "Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver" [J. Pharm. Biomed. Anal. 265 (2025) 117034].
Journal: Journal of pharmaceutical and biomedical analysis
Published: May 15, 2026
Pexidartinib in patients with tenosynovial giant cell tumor: a plain language summary of the final results from ENLIVEN.
Journal: Future oncology (London, England)
Published: May 14, 2026
PCO26-273: Development and Evaluation of a Crosslinked β-cyclodextrin Nanocarrier for Codelivery of Doxorubicin and Pexidartinib in Colorectal Cancer Therapy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 01, 2026
PCO26-273: Development and Evaluation of a Crosslinked β-cyclodextrin Nanocarrier for Codelivery of Doxorubicin and Pexidartinib in Colorectal Cancer Therapy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Discovery of novel CSF1R inhibitor for triple-negative breast cancer (TNBC) treatment through TAMs reprogramming.
Journal: Biochemical pharmacology
Published: February 10, 2026
Pharmacological Depletion of Retinal Mononuclear Phagocytes Is Neuroprotective in a Mouse Model of Mitochondrial Optic Neuropathy.
Journal: Investigative ophthalmology & visual science
Published: February 02, 2026
Investigating vimseltinib in tenosynovial giant cell tumors.
Journal: Expert opinion on pharmacotherapy
Published: January 25, 2026
High Risk of Drug-Drug Interactions Caused by Pexidartinib via UDP-Glucuronosyltransferases Inhibition.
Journal: Chemical research in toxicology
Published: January 23, 2026
Management of tenosynovial giant cell tumor: approved and investigational therapies.
Journal: Expert review of anticancer therapy
Published: January 20, 2026
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2025
Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.
Journal: Cancer metastasis reviews
Published: October 28, 2025
Targeting the DKK1/CSF1 signaling axis to reprogram M2 macrophages and reverse chemoresistance in head and neck squamous cell carcinoma.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: September 27, 2025
Last Updated: 06/30/2026